Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Aprogen, Inc (007460) Stock Price & Analysis

007460 Stock Chart & Stats

₩1,870.00-₩27.00(-1.42%)
At close: 3:30 PM GMT+9
KRW 2,000KRW 2,250KRW 2,5003 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
KRW 1,810.00 - KRW 1,921.00
52-Week Range
KRW 1,810.00 - KRW 14,070.00
Previous Close
KRW 1,897.00
Volume
N/A
Average Volume (3M)
127.95K
Market Cap
KRW 9.15B
Enterprise Value
KRW 546.23B
Total Cash (Recent Filing)
KRW 43.16B
Total Debt (Recent Filing)
KRW 181.45B
Price to Earnings (P/E)
―
Beta
0.27
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Revenue growth indicates that Aprogen’s biologics business is generating increasing top-line activity despite its weak earnings profile. If sustained, this expansion could provide a broader base for operating leverage and improve the commercial potential of its development and production capabilities.

Biologics Platform

Aprogen operates across biologic medicines, biosimilars, antibody therapeutics, recombinant proteins, and cell-culture technologies. This platform scope can support multiple development and production opportunities, giving the company durable exposure to biologics markets rather than a single product concept.

Additional Funding

The KRW 20 billion financing provides additional resources for corporate activities and potential expansion. Access to new capital can help Aprogen continue funding operations and its development pipeline over the next several months, although the convertible structure also carries financing implications.

Bears Say

Persistent Losses

Aprogen’s revenue growth has not translated into sustainable profitability: net losses remain deep and TTM profitability deteriorated despite the top-line rebound. This weak earnings conversion can constrain internal reinvestment and leaves the business dependent on continued funding to pursue growth.

Cash Burn

Consistently negative operating and free cash flow show that Aprogen is not currently self-funding its operations and investment needs. The worsening TTM free-cash-flow deficit increases reliance on external capital and may limit flexibility if funding requirements remain elevated.

Rising Leverage

The sharp increase in debt relative to equity has weakened Aprogen’s capital cushion while returns on equity remain materially negative. Higher leverage can increase financing pressure and reduce the company’s ability to absorb continued losses or fund development without further capital actions.

Aprogen, Inc News

007460 FAQ

What was Aprogen, Inc’s price range in the past 12 months?
Aprogen, Inc lowest stock price was ₩1810.00 and its highest was ₩14070.00 in the past 12 months.
What is Aprogen, Inc’s market cap?
Aprogen, Inc’s market cap is ₩9.15B.
When is Aprogen, Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aprogen, Inc’s earnings last quarter?
Aprogen, Inc released its earnings results on Aug 19, 2026. The company reported -₩1,182.482 earnings per share for the quarter.
Is Aprogen, Inc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Aprogen, Inc pay dividends?
Aprogen, Inc does not currently pay dividends.
What is Aprogen, Inc’s EPS estimate?
Aprogen, Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aprogen, Inc have?
Aprogen, Inc has 25,650,015 shares outstanding.
What happened to Aprogen, Inc’s price movement after its last earnings report?
Aprogen, Inc reported an EPS of -₩1,182.482 in its last earnings report. Following the earnings report the stock price went down -3.644%.
Which hedge fund is a major shareholder of Aprogen, Inc?
Currently, no hedge funds are holding shares in KR:007460
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology